micro-community-banner
Profile Image
  • Add Media
  • Saved

1yr
Innovative Cardiovascular Research Insights at AHA’s 100th Anniversary

At the American Heart Association’s centennial conference, Dr. Amit Khera, Director of Preventive Cardiology and Professor at UT Southwestern Medical Center, and Dr. John L. Sapp, Assistant Dean of Clinical Research at Dalhousie University, presented key findings. Topics included Tirzepatide’s impact on HFpEF and obesity, the comparison of left atrial appendage closure versus anticoagulation for atrial fibrillation, intensive blood pressure control in diabetes, and insights from the VANISH2 trial on ventricular tachycardia. These findings provide healthcare professionals with evidence-based strategies to advance cardiovascular care.

Profile Image
  • Saved

1yr
The Optimal Management of Patients with Atrial Fibrillation and Acute Heart Failure in the Emergency Department - PubMed

The Optimal Management of Patients with Atrial Fibrillation and Acute Heart Failure in the Emergency Department - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38138216/

Atrial fibrillation (AF) and acute heart failure (AHF) are two closely interrelated conditions that frequently coexist in a manifold manner, with AF serving either as the causative factor or as...

Atrial fibrillation (AF) and acute heart failure (AHF) are interlinked conditions with shared pathways. Effective emergency management involves acute rate/rhythm control, anticoagulation, and addressing symptoms to break the worsening cycle.

Profile Image
  • Saved

1yr
Heart failure biomarkers in hemodialysis patients - PubMed

Heart failure biomarkers in hemodialysis patients - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38994825/

The diagnosis of end-stage renal disease (ESRD) is made when the estimated glomerular filtration rate is less than 15 mL/min/1.73 m2. Most patients with that stage of chronic kidney disease...

End-stage renal disease increases cardiovascular risk, with heart failure and arrhythmias prevalent. This review explores natriuretic peptides and biomarkers in hemodialysis patients for assessing cardiovascular risk.

Profile Image
  • Saved

1yr
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment - PubMed

Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38602566/

The aetiology of heart failure with preserved ejection fraction (HFpEF) is heterogenous and overlaps with that of several comorbidities like atrial fibrillation, diabetes mellitus, chronic kidney disease, valvular heart disease,...

HFpEF involves heterogenous etiologies and comorbidities. Diagnosis relies on imaging, natriuretic peptides, and guideline-recommended algorithms. Sodium-glucose cotransporter-2 inhibitors show strong evidence, while beta-blockers are discouraged unless comorbidities warrant use.

Profile Image
  • Saved

1yr
Diuretic Treatment in Patients with Heart Failure: Current Evidence and Future Directions - Part I: Loop Diuretics - PubMed

Diuretic Treatment in Patients with Heart Failure: Current Evidence and Future Directions - Part I: Loop Diuretics - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38240883/

We will assess recent trials including DOSE, TRANSFORM, ADVOR, CLOROTIC, OSPREY-AHF, and PUSH-AHF amongst others, and assess how these may influence current practice and future research. There are few data...

Fluid retention in heart failure remains challenging; recent trials highlight high-dose loop diuretics' benefits over low-dose, yet guidelines lag. Improved research is crucial for advancing diuretic strategies and outcomes.

Profile Image